# A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults

> **NCT07085702** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 108 (estimated)

## Conditions studied

- Streptococcal Infections

## Interventions

- **BIOLOGICAL:** Low dose Strep A Alum
- **BIOLOGICAL:** Medium dose Strep A Alum
- **BIOLOGICAL:** High dose Strep A Alum
- **BIOLOGICAL:** Low dose Strep A AS37
- **BIOLOGICAL:** Medium dose Strep A AS37
- **BIOLOGICAL:** High dose Strep A AS37
- **DRUG:** Strep A Alum Placebo

## Key facts

- **NCT ID:** NCT07085702
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-31
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085702, "A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07085702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*